Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11376 - 11400 of 11972 in total
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of …
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
Matched Description: … By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one ... Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow …
1-Deoxy-D-xylulose 5-phosphate is a solid. This compound belongs to the pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups. The proteins that 1-Deoxy-D-xylulose 5-phosphate targets include 1-Deoxy-D-xylulose 5-phosphate reductoisomerase and pyridoxine 5'-phosphate synthase. 1-Deoxy-D-xylulose 5-phosphate is an intermediate in the non-mevalonate pathway.
Experimental
Matched Description: … 1-Deoxy-D-xylulose 5-phosphate is a solid. This compound belongs to the pentose phosphates. ... These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups. …
EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three...
Investigational
Matched Description: … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for ... combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a
Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM...
Illicit
Matched Description: … Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America ... Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl …
Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially...
Investigational
Matched Description: … The structure of vMIP consists of 71 residues and is a monomer under most conditions. ... Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog …
Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Investigational
Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.
Investigational
Matched Description: … Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers …
VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational
Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obtained from organ donor livers that are not suitable for whole organ transplantation.
Investigational
Matched Description: … Vesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration …
Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.
Experimental
Matched Description: … Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a
Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen).
Investigational
Matched Description: … clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Description: … Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single …
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
Matched Description: … TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy …
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Description: … ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 …
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
Investigational
Matched Description: … Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and …
BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the MVA-BN-brachyury-TRICOM vaccine and the fowlpox virus(FPV)‐Brachyury booster vaccine.
Investigational
Matched Description: … BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. …
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
Investigational
Matched Description: … It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate …
N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding...
Investigational
Withdrawn
Matched Description: … domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. ... [A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 ... and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding …
Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have...
Investigational
Matched Description: … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein …
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Investigational
Matched Description: … A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E …
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH. Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Matched Description: … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane ... Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for ... granted fast track status by the Food and Drug Administration due to promising initial results and a
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigational
Matched Description: … NGX267 is a muscarinic agonist. …
Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Investigational
Matched Description: … Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability …
Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).
Investigational
Matched Description: … Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics …
Displaying drugs 11376 - 11400 of 11972 in total